Premium
Analysis of the urine proteome in patients with pancreatic ductal adenocarcinoma
Author(s) -
Weeks Mark E.,
Hariharan Deepak,
Petronijevic Ljiljana,
Radon Tomasz P.,
Whiteman Hannah J.,
Kocher Hemant M.,
Timms John F.,
Lemoine Nicholas R.,
CrnogoracJurcevic Tatjana
Publication year - 2008
Publication title -
proteomics – clinical applications
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.948
H-Index - 54
eISSN - 1862-8354
pISSN - 1862-8346
DOI - 10.1002/prca.200780164
Subject(s) - pancreatic ductal adenocarcinoma , urine , pancreatitis , gelsolin , proteome , medicine , urinary system , adenocarcinoma , pancreas , gastroenterology , pancreatic cancer , biology , bioinformatics , cancer , biochemistry , actin
Pancreatic ductal adenocarcinoma (PDAC) accounts for over 213 000 deaths worldwide each year, largely due to late diagnosis. One of the risk factors for the development of PDAC is chronic pancreatitis (CP); the intense desmoplastic reaction makes differentiation between the two conditions extremely difficult. In order to identify biomarkers for noninvasive diagnosis, we performed 2‐D DIGE analysis of urine samples from healthy individuals and patients with PDAC and CP. Despite considerable intersample heterogeneity, a total of 127 statistically valid ( p <0.05), differentially expressed protein spots were detected, 101 of which were identified using MALDI‐TOF MS. A number of these, including annexin A2, gelsolin and CD59 have already been associated with PDAC, however, their validation using immunoblotting proved challenging. This is probably due to extensive PTMs and processing thus indicating the need for raising specific antibodies for urinary proteins. Despite this, our study clearly demonstrates that urine is a valid source of noninvasive biomarkers in patients with pancreatic diseases.